Thermodynamic Modeling of the Amorphous Solid Dispersion-Water Interfacial Layer and Its Impact on the Release Mechanism.

PC-SAFT amorphous solid dispersion (ASD) drug release escape glass transition (eGT) liquid-liquid phase separation (LLPS) phase behavior

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
19 May 2023
Historique:
received: 10 04 2023
revised: 12 05 2023
accepted: 16 05 2023
medline: 27 5 2023
pubmed: 27 5 2023
entrez: 27 5 2023
Statut: epublish

Résumé

During the dissolution of amorphous solid dispersion (ASD) formulations, the gel layer that forms at the ASD/water interface strongly dictates the release of the active pharmaceutical ingredient (API) and, hence, the dissolution performance. Several studies have demonstrated that the switch of the gel layer from eroding to non-eroding behavior is API-specific and drug-load (DL)-dependent. This study systematically classifies the ASD release mechanisms and relates them to the phenomenon of the loss of release (LoR). The latter is thermodynamically explained and predicted via a modeled ternary phase diagram of API, polymer, and water, and is then used to describe the ASD/water interfacial layers (below and above the glass transition). To this end, the ternary phase behavior of the APIs, naproxen, and venetoclax with the polymer poly(vinylpyrrolidone-co-vinyl acetate) (PVPVA64) and water was modeled using the perturbed-chain statistical associating fluid theory (PC-SAFT). The glass transition was modeled using the Gordon-Taylor equation. The DL-dependent LoR was found to be caused by API crystallization or liquid-liquid phase separation (LLPS) at the ASD/water interface. If crystallization occurs, it was found that API and polymer release was impeded above a threshold DL at which the APIs crystallized directly at the ASD interface. If LLPS occurs, an API-rich phase and a polymer-rich phase are formed. Above a threshold DL, the less mobile and hydrophobic API-rich phase accumulates at the interface which prevents API release. LLPS is further influenced by the composition and glass transition temperature of the evolving phases and was investigated at 37 °C and 50 °C regarding impact of temperature of. The modeling results and LoR predictions were experimentally validated by means of dissolution experiments, microscopy, Raman spectroscopy, and size exclusion chromatography. The experimental results were found to be in very good agreement with the predicted release mechanisms deduced from the phase diagrams. Thus, this thermodynamic modeling approach represents a powerful mechanistic tool that can be applied to classify and quantitatively predict the DL-dependent LoR release mechanism of PVPVA64-based ASDs in water.

Identifiants

pubmed: 37242781
pii: pharmaceutics15051539
doi: 10.3390/pharmaceutics15051539
pmc: PMC10221441
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

J Pharm Sci. 2012 Aug;101(8):2798-810
pubmed: 22592919
Mol Pharm. 2023 Jan 2;20(1):722-737
pubmed: 36545917
J Pharm Sci. 2017 Aug;106(8):1998-2008
pubmed: 28431965
Mol Pharm. 2022 Feb 7;19(2):392-413
pubmed: 34494842
Int J Pharm. 2013 Aug 30;453(1):253-84
pubmed: 22820134
Eur J Pharm Biopharm. 2021 Jan;158:132-142
pubmed: 33212185
Eur J Pharm Sci. 2015 Jan 25;67:21-31
pubmed: 25445833
Mol Pharm. 2020 Jul 6;17(7):2721-2733
pubmed: 32463685
Eur J Pharm Sci. 2021 Mar 1;158:105682
pubmed: 33347981
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):799-813
pubmed: 24056053
Mol Pharm. 2016 May 2;13(5):1467-81
pubmed: 27019407
J Control Release. 2019 Mar 28;298:68-82
pubmed: 30731151
J Pharm Sci. 2004 Jan;93(1):124-31
pubmed: 14648642
J Control Release. 2014 Aug 28;188:53-60
pubmed: 24910191
Mol Pharm. 2020 Apr 6;17(4):1261-1275
pubmed: 32134677
J Pharm Sci. 2014 Sep;103(9):2847-2858
pubmed: 24634063
Pharm Res. 1998 Aug;15(8):1202-6
pubmed: 9706050
Mol Pharm. 2018 Nov 5;15(11):5397-5409
pubmed: 30335401
Int J Pharm. 2002 Jan 14;231(2):131-44
pubmed: 11755266
Molecules. 2018 Jul 12;23(7):
pubmed: 30002275
Mol Pharm. 2019 Nov 4;16(11):4751-4754
pubmed: 31553871
J Pharm Sci. 2023 Jan;112(1):304-317
pubmed: 36306863
Pharm Res. 1995 Jun;12(6):799-806
pubmed: 7667182
Mol Pharm. 2019 Dec 2;16(12):5054-5067
pubmed: 31689113
Mol Pharm. 2021 Nov 1;18(11):3999-4014
pubmed: 34570503
Int J Pharm. 2015 Apr 10;483(1-2):256-67
pubmed: 25686660
Int J Pharm X. 2020 Dec 19;3:100070
pubmed: 33409486
Int J Pharm. 2018 Jan 15;535(1-2):245-252
pubmed: 29133204
Eur J Pharm Sci. 2019 Aug 1;136:104955
pubmed: 31199980
Int J Pharm X. 2021 Feb 25;3:100072
pubmed: 33855291
Mol Pharm. 2014 Nov 3;11(11):4189-98
pubmed: 25295846
Pharmaceutics. 2022 Sep 08;14(9):
pubmed: 36145652
Eur J Pharm Biopharm. 2000 Jul;50(1):47-60
pubmed: 10840192
Mol Pharm. 2018 Nov 5;15(11):5361-5373
pubmed: 30247922
Mol Pharm. 2018 Feb 5;15(2):669-678
pubmed: 29309155
Int J Pharm. 2014 Jul 20;469(1):159-67
pubmed: 24751346
Mol Pharm. 2017 Jan 3;14(1):157-171
pubmed: 28043133
Mol Pharm. 2015 Feb 2;12(2):496-503
pubmed: 25541813
Eur J Pharm Biopharm. 2015 Aug;94:352-62
pubmed: 26117187
Mol Pharm. 2017 Dec 4;14(12):4374-4386
pubmed: 29050468
Pharm Res. 1994 Apr;11(4):471-7
pubmed: 8058600
Mol Pharm. 2014 Jul 7;11(7):2294-304
pubmed: 24870944
Mol Pharm. 2019 Mar 4;16(3):1327-1339
pubmed: 30669846
Drug Discov Today Technol. 2012 Summer;9(2):e71-e174
pubmed: 24064267
Mol Pharm. 2015 May 4;12(5):1512-22
pubmed: 25872658
Pharm Res. 2015 Aug;32(8):2559-78
pubmed: 25715696
Eur J Pharm Biopharm. 2007 Jan;65(1):26-38
pubmed: 16962750
Molecules. 2017 Feb 15;22(2):
pubmed: 28212300

Auteurs

Stefanie Dohrn (S)

AbbVie Deutschland GmbH & Co. KG, Global Pharmaceutical R&D, Knollstraße, D-67061 Ludwigshafen am Rhein, Germany.

Samuel O Kyeremateng (SO)

AbbVie Deutschland GmbH & Co. KG, Global Pharmaceutical R&D, Knollstraße, D-67061 Ludwigshafen am Rhein, Germany.

Esther Bochmann (E)

AbbVie Deutschland GmbH & Co. KG, Global Pharmaceutical R&D, Knollstraße, D-67061 Ludwigshafen am Rhein, Germany.

Ekaterina Sobich (E)

AbbVie Deutschland GmbH & Co. KG, Global Pharmaceutical R&D, Knollstraße, D-67061 Ludwigshafen am Rhein, Germany.

Andrea Wahl (A)

AbbVie Deutschland GmbH & Co. KG, Global Pharmaceutical R&D, Knollstraße, D-67061 Ludwigshafen am Rhein, Germany.

Bernd Liepold (B)

AbbVie Deutschland GmbH & Co. KG, Global Pharmaceutical R&D, Knollstraße, D-67061 Ludwigshafen am Rhein, Germany.

Gabriele Sadowski (G)

Laboratory of Thermodynamics, Department of Chemical and Biochemical Engineering, TU Dortmund University, Emil-Figge-Str. 70, D-44227 Dortmund, Germany.

Matthias Degenhardt (M)

AbbVie Deutschland GmbH & Co. KG, Global Pharmaceutical R&D, Knollstraße, D-67061 Ludwigshafen am Rhein, Germany.

Classifications MeSH